The Center for Lung Disease and Transplantation at NewYork-Presbyterian/Columbia has earned a reputation for the depth of its clinical expertise and rigorous commitment to excellence.

Lung transplantation can prolong and dramatically improve the quality of life for patients with severe end-stage, non-malignant pulmonary disease and no alternative treatment options. Studies at the center continue to improve treatment options, prevent or delay the progression of serious lung diseases, and improve the quality of life and survival for patients. These achievements have been most notable in the areas of emphysema, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, and cystic fibrosis. The center is Medicare approved, and treats both adults and adolescents.

One of the oldest in the US, the Center was established in 1985, just three years after the first lung transplant was ever performed. Today, under the dynamic and collaborative leadership of its surgical and medical directors—both recognized as outstanding specialists in their respective fields—this highly reputable clinical and research center has been further enhanced and expanded.